🇺🇸 FDA
Pipeline program

mRNA-4157, Saline solution for Placebo to v940 (mrna-4157), KEYTRUDA 25 mg/mL concentrate for solution for infusion

V940-002

Phase 3 small_molecule active

Quick answer

mRNA-4157, Saline solution for Placebo to v940 (mrna-4157), KEYTRUDA 25 mg/mL concentrate for solution for infusion for Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials